Your patients need to understand that their medication is not the same as a mass-produced, FDA-approved drug
The most common approach: 1 ml water in a 5 mg vial 5 mg/ml (5000 mcg/ml) 2 ml water in a 5 mg vial 2.5 mg/ml (2500 mcg/ml) 1 ml water in a 2 mg Semaglutide vial 2 mg/ml a 0.5 mg dose = 25 units (U-100) The exact units to draw depend on your vial size, the water volume, and your dose
2024 doi: 10.1177/15598276241302273
These and other studies leave people optimistic that over extended periods of glutathione use can help whiten their skin
Paul Kalra Watch time: 12m 41s (2 videos) Video Heart Failure Prevention & Chronic Conditions ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad, et al Watch time: 22m 47s Video Series Heart Failure Prevention & Chronic Conditions e-SPACE CRM 2022 Andrew JS Coats, Stefan Anker Video Series Prevention & Chronic Conditions Cardiovascular Kidney Metabolic The Evidence-based CKD Clinic: Changing Practice with SGLT2 Inhibition David Wheeler, Carol Pollock, Media Video Cardiovascular Kidney Metabolic Heart Failure ESC HF 25: Kidney Function Trajectories Before and After HF Hospitalisation Nicolas Girerd Watch time: 4m 39s Video Prevention & Chronic Conditions Cardiovascular Kidney Metabolic AHA 24: 3 Trials That Will Change My Practice Michelle Kittleson Watch time: 10m 27s Video Prevention & Chronic Conditions Cardiovascular Kidney Metabolic AHA 24 Late-Breaking Discussion: REALIZE-K Harriette Van Spall, Mikhail Kosiborod Watch time: 22m 30s Video Prevention & Chronic Conditions Cardiovascular Kidney Metabolic ESC 24: The FINE-HEART Study Muthiah Vaduganathan Watch time: 4m 24s Video Prevention & Chronic Conditions Cardiovascular Kidney Metabolic HFA 24: Timing of Cardio-Kidney Protection with SGLT2i Muthiah Vaduganathan Watch time: 5m 24s Video Prevention & Chronic Conditions Cardiovascular Kidney Metabolic HFA 24: The FINE-HEART Study Muthiah Vaduganathan Watch time: 4m 40s Video Series Prevention & Chronic Conditions Cardiovascular Kidney Metabolic Hyperkalaemia in Cardiorenal Disease A Case Based Discussion James Burton, Shelley Zieroth, Clara Bonanad Lozano, et al Watch time: 18m (7 videos) Video Series Prevention & Chronic Conditions Cardiovascular Kidney Metabolic e-SPACE Cardio-Renal-Metabolic 2023 Fausto J Pinto, John Spertus, , et al Watch time: 2s (19 videos) Video Heart Failure Prevention & Chronic Conditions Insights from EMPA-Kidney: Methodology, Data & Impact Kate Wilcox, David Preiss Watch time: 38m 47s Video Series Heart Failure Prevention & Chronic Conditions The IRONMAN Trial: Does IV Iron Improve Outcomes in HF
This can make weight loss more difficult
